what is thymosin alpha 1: Frequently asked questions

Verify the CAS number on the certificate of analysis. If it reads 62304-98-7, you received the correct peptide. The hyphen is a labeling variation, not an indicator of product substitution. Cross-check the molecular weight (should be 3,108.3 Da) and HPLC purity (≥98% for research-grade). If those match and the amino-acid sequence is confirmed via mass spec as the standard 28-residue thymosin alpha chain, the product is identical regardless of hyphen presence.

Proceed with the non-hyphenated version if the CAS number matches. Research protocols reference the peptide's biological function, not its typographical presentation. The MyD88 signaling pathway and TLR9 receptor affinity remain unchanged. Document the CAS verification in your materials and methods section to clarify equivalence. If institutional review requires exact nomenclature matching, provide the supplier's CoA showing the CAS 62304-98-7 designation alongside the hyphen-free label. Regulators recognize CAS as the definitive identifier.

No. Thymosin alpha-1 and thymosin beta-4 are entirely different peptides with distinct sequences, mechanisms, and CAS numbers. Thymosin beta-4 (CAS 77591-33-4) is a 43-amino-acid actin-sequestering peptide involved in wound healing and cell migration, not immune modulation. The 'alpha' versus 'beta' designation denotes separate thymosin fractions isolated from thymic tissue. They are not naming variants of the same compound. If your research involves wound repair or cytoskeletal dynamics, thymosin beta-4 is the target. For immune system upregulation and T-cell maturation, thymosin alpha-1 is required.

No. Cloudiness or visible particulate formation in reconstituted thymosin alpha-1 peptide indicates protein aggregation or microbial contamination—both render the solution unusable. Properly reconstituted thymosin alpha-1 peptide in bacteriostatic water should be crystal clear and colorless. Aggregation occurs when peptide bonds form between separate thymosin alpha-1 molecules due to temperature excursions (storage above 8°C), pH shifts (using non-sterile water), or freeze-thaw cycles. Discard any cloudy solution immediately—injecting aggregated peptide risks injection site reactions and delivers zero therapeutic benefit because aggregated peptides cannot bind to Toll-like receptors.

No. Administer the missed dose as soon as you remember if fewer than 3 days have passed since the scheduled injection, then resume your regular twice-weekly schedule. If more than 3 days have elapsed, skip the missed dose entirely and continue with your next scheduled dose. Doubling up creates a supraphysiologic spike in Toll-like receptor activation that doesn't translate to improved immune response—TLR9 signaling saturates at peptide concentrations equivalent to approximately 3mg, so doses above 6.4mg provide no additional benefit and increase the risk of transient flu-like symptoms (fever, myalgia) from excessive interferon release.

Measurable immune marker changes—specifically, increases in CD4+ T-cell counts and reductions in viral load—typically appear 4–6 weeks into a thymosin alpha-1 peptide protocol at 1.6mg twice weekly. Monitor CBC with differential and viral PCR quantification at baseline, week 4, week 12, and week 24 to track response. Clinical trials in chronic hepatitis B show that responders (defined as >1 log reduction in HBV DNA) exhibit detectable CD4+ count increases by week 8, while non-responders show minimal change by week 12—suggesting that lack of immune marker response at 12 weeks predicts treatment failure and warrants protocol reassessment.